Autolus Therapeutics plc specializes in the research, development, and commercialization of cell therapies, utilizing T cell programming technologies originally spun out of University College London. The company's core focus is on chimeric antigen receptor (CAR) T cell therapies, which involve extracting a patient's immune cells, genetically modifying them to recognize cancer cells, and infusing them back into the patient. Its lead commercial product, AUCATZYL (obe-cel), received FDA approval in 2024 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Beyond its commercial operations in the United States and the United Kingdom, Autolus maintains a clinical pipeline targeting other hematological malignancies, solid tumors, and autoimmune diseases such as lupus nephritis and multiple sclerosis. The company operates manufacturing and research facilities in the UK and the US to support its global clinical and commercial activities.
